{
    "guideline_identifier": "PIIS2059702924007452.txt",
    "cancer_focus": {
        "primary_cancer": "Merkel Cell Carcinoma (MCC)",
        "related_syndrome_or_condition": "Immunosuppression-related conditions (organ transplant recipients, hematological malignancies, HIV infection)"
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Stage IA (T1 N0 M0)",
            "risk_group": "Low risk",
            "treatment_plans": [
                {
                    "clinical_context": "Local/Locoregional Disease",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Wide Local Excision (WLE) with 1–2 cm margins; Mohs surgery acceptable in selected cases. Adjuvant radiotherapy (RT) mandatory for tumors ≥1 cm, high-risk features, or margins <1 cm (50–60 Gy to tumor bed). Sentinel lymph node biopsy (SLNB) recommended for clinically node-negative disease.",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level III (for SLNB), Level IV (for RT)"
                },
                {
                    "clinical_context": "Positive SLNB findings",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Adjuvant RT ± Complete Lymph Node Dissection (CLND)",
                    "treatment_line": "Adjuvant",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IV"
                }
            ]
        },
        {
            "staging_criteria": "Stage IIB–III (T2–T4, N1–N3, M0)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "clinical_context": "Local/Locoregional Disease",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Wide Local Excision (WLE) with 1–2 cm margins + mandatory adjuvant RT (50–60 Gy). For clinically positive nodes: CLND + adjuvant RT or definitive RT if inoperable. For in-transit metastases: Surgery/RT or isolated limb perfusion.",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IV"
                },
                {
                    "clinical_context": "Unknown Primary (T0 N1b M0)",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Nodal dissection + adjuvant RT (treated as stage IIIB)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IV"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (M1)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "clinical_context": "Advanced/Metastatic Disease",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "First-line immunotherapy: Avelumab (anti-PD-L1), Pembrolizumab (anti-PD-1), Retifanlimab (anti-PD-1), or Nivolumab (investigational)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level I (for Avelumab)"
                },
                {
                    "clinical_context": "Subsequent Therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Second-line: Palliative RT or chemotherapy (platinum-etoposide, taxanes). Third-line: Best supportive care or clinical trials",
                    "treatment_line": "Second-line and beyond",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IV"
                },
                {
                    "clinical_context": "Oligometastatic Disease",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Surgical resection or stereotactic RT if feasible",
                    "treatment_line": "Varies",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IV"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "Diagnostic: IHC panel (CK20, chromogranin A, synaptophysin, CD56) confirms MCC. Prognostic: Favorable—CD8+ T-cell infiltration, MCPyV positivity; Unfavorable—p63 expression, high mitotic rate, lymphovascular invasion. Non-predictive for therapy: PD-L1 expression, tumor mutational burden."
    }
}